SEC Form 4 · accession 0001214659-18-007701
HUMANIGEN, INC · HGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cameron Durrant
Officer — Chief Executive Officer · Director
Period of report
Dec 12, 2018
Accepted (ET)
Dec 14, 2018 · 7:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293310
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value | Dec 12, 2018 | A | 2,000 | $0.8219 | A | 159,583 | D | |
| Common Stock, $0.001 par valueF1 | Dec 14, 2018 | A | 4,000 | $0.816 | A | 163,583 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in this cell is a weighted average price. On December 14, 2018, Dr. Durrant purchased 4,000 shares in multiple transactions at prices ranging from $0.802 to $0.8299, inclusive. The reporting person undertakes to provide to Humanigen, Inc., any security holder of Humanigen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.